#United States #Nashville #Petauri #Mtech Access #Delta Hat

Petauri's Strategic Move: Uniting Mtech Access and Delta Hat Under Petauri Evidence

In a significant development in the pharmaceutical services sector, Petauri has launched Petauri Evidence, a new business unit aimed at revolutionizing evidence generation and market access solutions. Founded on the successful legacies of Mtech Access and Delta Hat, this initiative signifies a strategic restructuring that seeks to enhance the delivery of healthcare insights to pharmaceutical and life sciences companies.

Integration of Expertise

The creation of Petauri Evidence is designed to seamlessly integrate the strengths of both Mtech Access's pricing and market access expertise with Delta Hat's analytics and health economics capabilities. This merger creates a powerful platform that is positioned to deliver deep insights and impactful strategies to their clients. By embodying a comprehensive suite of specialized services, Petauri Evidence aims to provide unprecedented value to stakeholders within the pharmaceutical industry.

Dan Renick, CEO of Petauri, expressed excitement over this integration, highlighting how the union will improve their capability to support clients in evidence generation and payer engagement. He stated that this evolution allows for better healthcare decisions driven by enhanced value communications.

Leadership and Vision

At the helm of this newly formed unit is David Niziol, cofounder of Mtech Access, who takes on the role of President of Petauri Evidence. His extensive experience in health economics and value communication strategies is expected to drive the unit towards achieving its goals of delivering actionable insights and real-world evidence that can aid clients in overcoming complex access challenges. Niziol elaborated that combining strengths from both organizations will facilitate innovative evidence solutions that illustrate the true value of their clients' products.

Anthony Hatswell, founder of Delta Hat and the newly appointed Chief Scientific Officer for Petauri Evidence, emphasized the enhanced capabilities this integration brings. He acknowledged the value of bringing Delta Hat's analytical expertise into the fold, which aligns with Petauri's objective of expanding insights for healthcare stakeholders.

Commitment to Innovation

Petauri Evidence will continue to push the boundaries of evidence strategies and services, helping pharmaceutical and life sciences companies navigate the intricate global healthcare landscape. Clients can anticipate a more enriched suite of offerings aimed at optimizing product value and improving access to innovative therapies for patients.

Since its establishment in 2023, Petauri has focused on merging top-tier companies that specialize in areas such as market access, medical affairs, and analytics. The substantial investment from Oak Hill Capital, amounting to over $250 million, highlights a commitment to fostering growth and innovation in the pharmaceutical services sector. Petauri’s initiatives aim not only to enhance client capabilities but also to ultimately improve patient outcomes through a better understanding of the health economics involved in medical advancements.

For more information on Petauri and its services, you can visit their website at Petauri.